Hologic (HOLX)
(Delayed Data from NSDQ)
$74.51 USD
-0.27 (-0.36%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $74.49 -0.02 (-0.03%) 4:34 PM ET
2-Buy of 5 2
B Value D Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$74.51 USD
-0.27 (-0.36%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $74.49 -0.02 (-0.03%) 4:34 PM ET
2-Buy of 5 2
B Value D Growth C Momentum C VGM
Zacks News
Here's Why Investors Should Hold Align Technology (ALGN) Now
by Zacks Equity Research
Investors are optimistic about Align Technology's (ALGN) Invisalign portfolio expansion and strategic alliances.
Quest Diagnostics' (DGX) New Pact to Get Home Fertility Test
by Zacks Equity Research
The Proov Confirm home collection kit can be purchased now on Quest Diagnostics' questhealth.com for $29.
Here's Why You Should Retain Chemed (CHE) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Chemed (CHE) on the strength of the VITAS Healthcare and Roto-Rooter segments.
Stryker (SYK) Launches Autonomous Guidance System for Surgeries
by Zacks Equity Research
Stryker's (SYK) fully autonomous Ortho Q Guidance system offers smart and streamlined workflow, leading to enhanced procedural speed and efficiency.
3 Reasons to Retain PacBio (PACB) Stock in Your Portfolio
by Zacks Equity Research
PacBio's (PACB) product development activities raise optimism about the stock.
Reasons to Retain ShockWave Medical (SWAV) in Your Portfolio
by Zacks Equity Research
ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.
Reasons to Retain AMN Healthcare (AMN) Stock in Your Portfolio
by Zacks Equity Research
Investors remain optimistic about AMN Healthcare's (AMN) broad array of services.
Here's Why You Should Add Stryker (SYK) Stock to Your Portfolio
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio. However, pricing pressure weighs on the stock.
Hologic (HOLX) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Hologic (HOLX) closed at $78.83, marking a -1.29% move from the previous day.
Myomo's (MYO) MyoPro Seeks CMS Classification for Medicare Cover
by Zacks Equity Research
If this rule is finalized without any changes to reimbursement practices, Myomo's (MYO) MyoPro could be reimbursed in a lump-sum manner by CMS.
DexCom's (DXCM) G7 CGM System Gets Nod From Health Canada
by Zacks Equity Research
DexCom's (DXCM) G7 CGM System's latest approval by Health Canada is expected to combine simplicity and power, thereby providing a better way to manage diabetes.
LabCorp (LH) Partners With Forge Biologics for Gene Therapies
by Zacks Equity Research
LabCorp's (LH) latest partnership will significantly assist patients gain access to cutting-edge, potentially life-saving medication.
Here's Why You Should Retain Teleflex (TFX) Stock for Now
by Zacks Equity Research
Revenue growth across global product categories and a broad geographic footprint bode well for Teleflex (TFX).
Hologic, Inc. (HOLX) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Hologic (HOLX). This makes it worthwhile to examine what the stock has in store.
Reasons to Retain AmerisourceBergen (ABC) in Your Portfolio
by Zacks Equity Research
AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
3 Reasons to Retain NextGen (NXGN) Stock in Your Portfolio
by Zacks Equity Research
NextGen's (NXGN) strong product portfolio and continued demand for its solutions raise optimism about the stock.
Here's Why You Should Buy Exact Sciences (EXAS) Stock Now
by Zacks Equity Research
Investors are optimistic about Exact Sciences (EXAS) on strong Cologuard growth and raised guidance.
Reasons to Add Inari Medical (NARI) Stock to Your Portfolio
by Zacks Equity Research
Inari Medical (NARI) continues to benefit from its commitment to understand the venous system. However, its dependency on adoption of products is a concern.
McKesson (MCK) Hits 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Investors are optimistic about McKesson's (MCK) strength in its Biologics business.
Integer Holdings (ITGR) Hits 52-Week High: What's Aiding It?
by Zacks Equity Research
Investors are optimistic about Integer Holdings' (ITGR) solid foothold in the broader MedTech space.
Canopy Growth (CGC) Improves Liquidity With Another Selloff
by Zacks Equity Research
Canopy Growth's (CGC) decision to divest facilities aligns with its organizational transformation plan.
Here's Why You Should Invest in Neogen (NEOG) Stock Now
by Zacks Equity Research
Investors are upbeat about Neogen (NEOG) owing to strong performance across its Animal Safety and Food Safety segments.
Stryker (SYK) Stock Hits 52-Week High: More Room to Grow?
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio. However, pricing pressure weighs on the stock.
West Pharmaceutical (WST) Hits 52-Week High: More Room to Grow?
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.
Here's Why You Should Retain Zimmer Biomet (ZBH) for Now
by Zacks Equity Research
Investors are optimistic about Zimmer Biomet (ZBH) due to the continued procedure recovery and the strength of emerging markets.